Insider Selling: Eton Pharmaceuticals (NASDAQ:ETON) Insider Sells 42,797 Shares of Stock

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) insider David Krempa sold 42,797 shares of the business’s stock in a transaction on Friday, May 22nd. The stock was sold at an average price of $33.39, for a total transaction of $1,428,991.83. Following the sale, the insider directly owned 25,249 shares in the company, valued at approximately $843,064.11. The trade was a 62.89% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

David Krempa also recently made the following trade(s):

• On Tuesday, May 26th, David Krempa sold 37,524 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $31.49, for a total transaction of $1,181,630.76.
• On Wednesday, May 27th, David Krempa sold 19,679 shares of Eton Pharmaceuticals stock. The stock was sold at an average price of $31.47, for a total transaction of $619,298.13.

Eton Pharmaceuticals Trading Up 3.5%

Shares of NASDAQ:ETON traded up $1.11 during mid-day trading on Wednesday, reaching $32.40. 442,334 shares of the company’s stock were exchanged, compared to its average volume of 358,595. The firm has a market capitalization of $887.50 million, a price-to-earnings ratio of -462.79 and a beta of 0.82. The business’s fifty day moving average price is $26.33 and its 200-day moving average price is $19.94. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.88 and a current ratio of 1.21. Eton Pharmaceuticals, Inc. has a twelve month low of $13.09 and a twelve month high of $35.66.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Thursday, May 14th. The company reported $0.05 EPS for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). The business had revenue of $24.27 million for the quarter, compared to analyst estimates of $22.31 million. Eton Pharmaceuticals had a negative return on equity of 5.68% and a negative net margin of 1.70%. On average, research analysts predict that Eton Pharmaceuticals, Inc. will post 0.82 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts have recently commented on the stock. Wall Street Zen upgraded shares of Eton Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday, March 21st. HC Wainwright lifted their price target on shares of Eton Pharmaceuticals from $52.00 to $57.00 and gave the stock a “buy” rating in a report on Friday, May 15th. Zacks Research lowered shares of Eton Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Friday, April 17th. Craig Hallum lifted their price target on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a report on Friday, March 20th. Finally, B. Riley Financial lifted their price target on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the stock a “buy” rating in a report on Friday, March 20th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Eton Pharmaceuticals currently has a consensus rating of “Hold” and an average price target of $41.00.

Hedge Funds Weigh In On Eton Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Bank of America Corp DE lifted its holdings in Eton Pharmaceuticals by 37.8% in the first quarter. Bank of America Corp DE now owns 144,367 shares of the company’s stock valued at $3,563,000 after buying an additional 39,571 shares during the period. EcoR1 Capital LLC lifted its holdings in Eton Pharmaceuticals by 7.0% in the first quarter. EcoR1 Capital LLC now owns 2,171,938 shares of the company’s stock valued at $53,603,000 after buying an additional 141,394 shares during the period. Aristides Capital LLC lifted its holdings in Eton Pharmaceuticals by 15.2% in the first quarter. Aristides Capital LLC now owns 186,041 shares of the company’s stock valued at $4,591,000 after buying an additional 24,605 shares during the period. Bank of Nova Scotia acquired a new position in Eton Pharmaceuticals in the first quarter valued at $365,000. Finally, Sei Investments Co. acquired a new position in Eton Pharmaceuticals in the first quarter valued at $1,432,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.